Mutations in the IDH1 and IDH2 genes are well described in lower-grade gliomas (grade II and III astrocytomas and oligodendrogliomas) and secondary glioblastomas, where they have an incidence of more than 70 %. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).